921598-18-7

Upstream product

• 808768-96-9 2-[3-(2-hydroxy-2-methylpropyl)phenyl]acetic acid 
• 545-06-2 trichloroacetonitrile 

Downstream Products

• 921598-21-2 2-[3-(2-amino-2-methylpropyl)phenyl]-N-[(4'-hydroxybiphenyl-3-yl)methyl]acetamide 
• 921598-25-6 2-(3-{2-[((2R)-2-{4-benzyloxy-3-[(methylsulfonyl)amino]phenyl}-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]-2-methylpropyl}phenyl)-N-[(4'-hydroxybiphenyl-3-yl)methyl]-acetamide 
• 921598-22-3 2-[3-(2-{[(2R)-2-{4-(benzyloxy)-3-[(methylsulfonyl)amino]-phenyl}-2-hydroxyethyl]amino}-2-methylpropyl)phenyl]-N-[(4'-hydroxybiphenyl-3-yl)methyl]acetamide 
• 862540-80-5 2-[3-(2-{[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl]amino}-2-methylpropyl)phenyl]-N-[(4'-hydroxybiphenyl-3-yl)methyl]acetamide 

Relevant academic research and scientific papers

Development of a potential manufacturing route to PF-00610355: A novel inhaled β2-adrenoreceptor agonist

The development of a practical, scalable route to PF-00610355 (8) is described. In this convergent approach, amine 9 is coupled to protected bromohydrin 1 to give the doubly protected intermediate 26. TBS-Deprotection of 26 affords the benzyl protected pe

PROCESS FOR THE PREPARATION OF SULFONAMIDE DERIVATIVES

The invention relates to a process for the preparation of compounds of formula (I) wherein Q1 is a group selected from formulae (II and (III) and a group *-NR6 -Q2-A or, if appropriate, their pharmaceutically acceptable sa